Baird Keeps Neutral on Celgene

Analyst Christopher Raymond says the cancer drug developer provides an increasingly positive efficacy profile for its drug Revlimid but is still not without risk

Baird keeps neutral on cancer drug developer Celgene Corp. (CELG ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.